JP
Revvity Sites Globally
Select your location.
*e-commerce not available for this region.
Literature - Publication Review
Bone morphogenetic protein 8B - a promising therapeutic avenue for NASH treatment
The incidence and prevalence of non-alcoholic fatty liver disease (NAFLD), which is characterized by excessive accumulation of lipids within the liver, is progressively rising due to increasing obesity and metabolic syndrome prevalence. For some individuals, NAFLD can progress to non-alcoholic steatohepatitis (NASH), which can lead to liver cirrhosis and hepatocellular carcinoma (HCC). NASH is poorly understood and therapies to treat the disease are lacking. Michele Vacca, from the University of Cambridge in the UK and colleagues sought to investigate the impact of one member of the TGFß-BMP superfamily, BMP8B, on the progression of NASH. Learn more about their study.
For research use only. Not for use in diagnostic procedures.
To view the full content please answer a few questions
Download Resource
Bone morphogenetic protein 8B - a promising therapeutic avenue for NASH treatment